Ad is loading...
MENU

REGN Stock Regeneron Pharmaceuticals (REGN, $743.35) entered a weekly bearish trend. Expect a Downtrend continuation

A.I.dvisor
at Tickeron.com
Loading...
REGN - Regeneron Pharmaceuticals
Bearish Trend Signal
Bearish Trend
Odds of DOWN Trend
Tickeron

Loading...

Price: $743.35
Daily change: -$1.25 (-0.17%)
Daily volume: 651.8K
Capitalization: $81.7B
Industry: Biotechnology
Regeneron Pharmaceuticals (REGN, $743.35) is predicted by A.I.dvisor to decline by to $728.48 or more within the next week. Following its losing streak extending for a consecutive week, REGN is expected to continue dropping based on similar cases which trended down, making the odds of a Downtrend continuation

REGN's Indicator enters downward trend

The Aroon Indicator for REGN entered a downward trend on November 20, 2024. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 153 similar instances where the Aroon Indicator formed such a pattern. In of the 153 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for REGN turned negative on October 21, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 50-day moving average for REGN moved below the 200-day moving average on November 12, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in of 324 cases, the price rose further within the following month. The odds of a continued upward trend are .

REGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. REGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.790) is normal, around the industry mean (13.752). P/E Ratio (18.417) is within average values for comparable stocks, (88.017). Projected Growth (PEG Ratio) (1.108) is also within normal values, averaging (1.790). REGN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (6.192) is also within normal values, averaging (224.437).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
REGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of medicines for the treatment of serious medical conditions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
777 Old Saw Mill River Road
Phone
+1 914 847-7000
Employees
13450
Web
https://www.regeneron.com